| Document |
Document Title |
|
WO/2023/181053A1 |
The present invention relates to an improved process for purification of Robenacoxib. More particularly, the present invention relates to a process for obtaining crystalline Robenacoxib in high yield with high purity. Furthermore, the pr...
|
|
WO/2023/180955A1 |
Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of various neurological disorders in humans.
|
|
WO/2023/180976A1 |
The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and...
|
|
WO/2023/181075A1 |
The present application relates to amorphous solid dispersions of Deucravacitinib, process for the preparation of amorphous solid dispersion of Deucravacitinib, process for the preparation crystalline form of Deucravacitinib and process ...
|
|
WO/2023/180956A1 |
Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of spasticity in humans.
|
|
WO/2023/183059A1 |
The present invention provides a method of treating pathological inflammation in a patient comprising: administering to the patient a multivalent structured polypeptide comprising at least one therapeutic peptide. The present invention a...
|
|
WO/2023/180125A1 |
The present invention relates to novel somatostatin 4 (SST4) selective agonists as non- opioid analgesics. In particular, the present invention relates to peptides having strong SST4-selectivity for use in treatment of pain or inflammation.
|
|
WO/2023/180954A1 |
Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the prevention, treatment, and control of various inflammatory disorders in humans.
|
|
WO/2023/174941A1 |
The present specification discloses pharmaceutical composition disclosed herein comprises one or more fibrates, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats an...
|
|
WO/2023/177351A1 |
The present disclosure concerns compounds and methods thereof for treating proliferative diseases, fibrosis, inflammatory diseases and/or immune inflammatory 5 diseases. The present disclosure also concerns methods of inhibiting NF-κB-i...
|
|
WO/2023/177249A1 |
The present invention pertains to a novel binary Histone deacetylase (HDAC) inhibitor, and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits more selective and super...
|
|
WO/2023/176952A1 |
The purpose of the present invention is to provide a means for controlling the proliferation of a bacterium in the intestine. Provided is a composition for controlling the proliferation of any one bacterium selected from the group consis...
|
|
WO/2023/176951A1 |
Provided is a means for controlling proliferation of Collinsella bacteria in the intestines. The present invention addresses the problem of providing a novel material that is capable of controlling proliferation of Collinsella bacteria. ...
|
|
WO/2023/174138A1 |
Disclosed are an amide compound as represented by formula I, and a preparation method therefor and the use thereof. The disclosed amide compound has selective inhibitory activity on Nav1.8 and can be used as a selective inhibitor for Nav...
|
|
WO/2023/174265A1 |
Provided are a recombinant adeno-associated virus for treating inflammatory diseases, and a construction method therefor and the use thereof. The recombinant adeno-associated virus uses an adeno-associated virus as a vector, and comprise...
|
|
WO/2023/176977A1 |
Provided is a method capable of industrially advantageously manufacturing a labiatae extract containing a rosmarinic acid at a high concentration. The method for manufacturing a labiatae hot-water extract comprises steps (A) and (B): (...
|
|
WO/2023/174409A1 |
The present invention relates to a salt form and a crystal form of a Vanin enzyme inhibitor represented by formula I, a method for preparing same, and use thereof. The salt form is a salt formed by the compound represented by formula I w...
|
|
WO/2023/177250A1 |
The present invention relates to a novel heterocyclic inhibitor for histone deacetylase (HDAC), a novel therapeutic agent for HDAC-associated diseases, and a pharmaceutical composition comprising same. More specifically, a compound accor...
|
|
WO/2023/173173A1 |
The present disclosure relates to methods of treating a subject suffering from an eosinophil-associated chronic obstructive pulmonary disease (COPD) or asthma-COPD overlap (ACO) using compounds that bind to CD131 and inhibit signalling o...
|
|
WO/2023/174300A1 |
Disclosed in the present invention are a crystal form of a BTK inhibitor, an acid salt thereof, and a crystal form of the acid salt thereof. The crystal form of a compound of formula I in the present invention is a free alkali crystal fo...
|
|
WO/2023/174463A1 |
The present invention provides a method of preparation of a biological therapeutic product based on perinatal tissue, characterized in that the method includes the steps of: a) cleaning of the starting perinatal tissue and optionally its...
|
|
WO/2023/177146A1 |
The present disclosure relates to: a novel thiadiazole derivative compound; and a pharmaceutical composition for preventing or treating inflammatory diseases, the composition including the novel thiadiazole derivative compound as an acti...
|
|
WO/2023/178204A1 |
The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder...
|
|
WO/2023/176950A1 |
Provided is a means for controlling the proliferation of any one bacterium selected from the group consisting of a bacterium belonging to the genus Faecalibacterium, a bacterium belonging to the genus Akkermansia, a bacterium belonging t...
|
|
WO/2023/169453A1 |
The present invention relates to a heteroaromatic ring-containing alkynyl compound, and a preparation method therefor and the use thereof. The heteroaromatic ring-containing alkynyl compound is a compound represented by a formula (I), or...
|
|
WO/2023/171873A1 |
A solid lipid composite nanoethosomes according to an embodiment of the present invention comprises: a liposome structure comprising a dual layer of phosphatide and a hollow; a solid lipid located within the dual layer of phosphatide; an...
|
|
WO/2023/168830A1 |
The present invention belongs to the technical field of biomedicine, and specifically relates to an HEMTAC small molecule degradation agent and the use thereof. In the present invention, it is discovered via research that the HEMTAC smal...
|
|
WO/2023/173054A1 |
The present invention relates to preventing or inhibiting the formation of M2 monocytes and/or preventing or inhibiting monocyte trafficking/infiltration/migration to inflamed sites in a subject in need thereof, e.g., a subject having or...
|
|
WO/2023/169336A1 |
The present invention relates to the field of pharmaceutical chemistry, and provides a pyridazine compound, a preparation method therefor, and a use thereof. The compound is a compound as shown in formula I, or a stereoisomer thereof, or...
|
|
WO/2023/172148A1 |
This invention relates to the use of paracetamol, ibuprofen and xylometazoline (or a pharmaceutically acceptable salt thereof) in the production of a medication for use in treating cold and/or flu in a human, by administering or taking: ...
|
|
WO/2023/169548A1 |
Provided is an RNA inhibitor or a pharmaceutically acceptable salt thereof for inhibiting LPA gene expression, the RNA inhibitor comprising a complementary region of an antisense strand, and the complementary region comprising at least 1...
|
|
WO/2023/169372A1 |
A cucurbitacin B derivative, a preparation method therefor and a use thereof. The structure of the compound is shown in formula I. The cucurbitacin B derivative is easy to synthesize, has good anti-tumor and anti-inflammatory activity, a...
|
|
WO/2023/171714A1 |
[Problem] To provide a novel therapeutic agent, for bronchial asthma, that focuses on CD109. [Solution] This pharmaceutical composition contains, as an active component, a drug that improves bronchial hypersensitivity and/or eosinophilic...
|
|
WO/2023/170597A1 |
There is described a topical composition for treating injuries or cutaneous inflammatory states or proctological pathologies, comprising butyric acid or a salt thereof at a fraction by weight between 1% and 50% and zinc oxide at a fracti...
|
|
WO/2023/171894A1 |
The present invention relates to a pharmaceutical composition including docetaxel and a pharmaceutically acceptable salt thereof and a preparation method therefor. The present invention relates to a composition capable of increasing the ...
|
|
WO/2023/170585A1 |
The present invention relates to crystalline salts of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]
indol-3-yl)acetic acid, and pharmaceutical compositions comprising them that are useful as S1P1...
|
|
WO/2023/169073A1 |
The present invention relates to the technical field of medical materials. Provided in the present disclosure are a periodontal topical delivery preparation, and a preparation method therefor and the use thereof. The method for preparing...
|
|
WO/2023/167563A1 |
The present invention relates to a method for biosynthesizing N-carbamyl-L-glutamic acid and a novel use thereof for the prevention or treatment of inflammatory diseases. The invention also relates to a composition for the prevention, am...
|
|
WO/2023/167066A1 |
[Problem] To find a novel pharmaceutical or method for treating autoimmune diseases. [Solution] A combination of methotrexate and 5-ALAs.
|
|
WO/2023/165551A1 |
The present application relates to a six-membered aromatic ring-pyrrolidone derivative, and a pharmaceutical composition thereof and the use thereof. The six-membered aromatic ring-pyrrolidone derivative has the structure as shown in for...
|
|
WO/2023/166206A1 |
The present invention provides an IL-18 inhibitor for use in the treatment of VEXAS syndrome or symptoms associated with VEXAS syndrome in a subject.
|
|
WO/2023/165477A1 |
The present invention relates to a nucleic acid molecule encoding an interleukin 1 receptor antagonist protein, a transgenic expression cassette comprising the nucleic acid molecule, a gene delivery system comprising the transgenic expre...
|
|
WO/2023/168087A1 |
The present disclosure provides methods and compositions that involve inhibiting an activity of epiregulin in a cell, as well as reversing or preventing a change(s) in a cell, associated with a disease or disorder, e.g., a fibrotic disea...
|
|
WO/2023/133634A9 |
Described herein are cell populations comprising leukocyte lineage cells expressing one or more of CD16 and/or CD11b loaded with an agent, optionally an imaging agent, biologic or synthetic therapeutic, their method of making and their u...
|
|
WO/2023/097398A9 |
A composition is provided for treating and/or preventing inflammation in a subject comprising A-type proanthocyanidin (PAC-A) and zinc. The composition can include between 0.001 wt% and 10 wt% of PAC-A, and between 0.01 wt% and 25 wt% of...
|
|
WO/2023/164847A1 |
The present invention provides a combinational anti-cancer therapy with a CTLA-4 inhibitor and a non-steroidal anti-inflammatory drug. Specifically, the present invention provides a product combination comprising: (i) a first pharmaceuti...
|
|
WO/2023/168367A1 |
The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
|
|
WO/2023/165570A1 |
The present invention relates to a compound of formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutical composition thereof, and a use of the compound...
|
|
WO/2023/165574A1 |
Disclosed are a compound used as a TYK2 inhibitor, a preparation method therefor, and pharmaceutical use thereof. Specifically, the compound has a structure represented by formula (I), wherein the definitions of the groups and substituen...
|
|
WO/2023/165554A1 |
The present application relates to the technical field of chemical drugs, and relates to a deuterated compound represented by general formula (I), or a racemate thereof, or an isomer thereof, or a pharmaceutically acceptable salt thereof...
|
